Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Medical Oncology 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × roniciclib × Clear all
NCT01573338 2021-04-08

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Bayer

Phase 1/2 Terminated
43 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02161419 2018-06-25

CONCEPT-SCLC

Bayer

Phase 2 Terminated
142 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01188252 2017-01-09

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

Bayer

Phase 1 Completed
112 enrolled
Tumor-Agnostic

Neoplasms

NCT02390154 2016-07-15

Roniciclib Mass Balance Study

Bayer

Phase 1 Completed
7 enrolled
Tumor-Agnostic

Neoplasms

NCT02457351 2016-05-23

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Bayer

Phase 1 Completed
14 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡